444 related articles for article (PubMed ID: 31323387)
21. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
23. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
Vokes NI; Chambers E; Nguyen T; Coolidge A; Lydon CA; Le X; Sholl L; Heymach JV; Nishino M; Van Allen EM; Jänne PA
J Thorac Oncol; 2022 Jun; 17(6):779-792. PubMed ID: 35331964
[TBL] [Abstract][Full Text] [Related]
24. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
Vokes NI; Galan Cobo A; Fernandez-Chas M; Molkentine D; Treviño S; Druker V; Qian Y; Patel S; Schmidt S; Hong L; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee JJ; Negrao MV; Gibbons DL; Vaporciyan A; Le X; Wu J; Zhang J; Rigney U; Iyer S; Dean E; Heymach JV
Clin Cancer Res; 2023 Dec; 29(23):4958-4972. PubMed ID: 37733794
[TBL] [Abstract][Full Text] [Related]
25.
Binkley MS; Jeon YJ; Nesselbush M; Moding EJ; Nabet BY; Almanza D; Kunder C; Stehr H; Yoo CH; Rhee S; Xiang M; Chabon JJ; Hamilton E; Kurtz DM; Gojenola L; Owen SG; Ko RB; Shin JH; Maxim PG; Lui NS; Backhus LM; Berry MF; Shrager JB; Ramchandran KJ; Padda SK; Das M; Neal JW; Wakelee HA; Alizadeh AA; Loo BW; Diehn M
Cancer Discov; 2020 Dec; 10(12):1826-1841. PubMed ID: 33071215
[TBL] [Abstract][Full Text] [Related]
26. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
27. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma.
Best SA; Ding S; Kersbergen A; Dong X; Song JY; Xie Y; Reljic B; Li K; Vince JE; Rathi V; Wright GM; Ritchie ME; Sutherland KD
Nat Commun; 2019 Sep; 10(1):4190. PubMed ID: 31519898
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
29. Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.
Best SA; De Souza DP; Kersbergen A; Policheni AN; Dayalan S; Tull D; Rathi V; Gray DH; Ritchie ME; McConville MJ; Sutherland KD
Cell Metab; 2018 Apr; 27(4):935-943.e4. PubMed ID: 29526543
[TBL] [Abstract][Full Text] [Related]
30.
Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
[TBL] [Abstract][Full Text] [Related]
31. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
32. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
[TBL] [Abstract][Full Text] [Related]
33. KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed. Reply to "KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis".
Mazzotta M; Marinelli D; Maugeri-Saccà M
J Thorac Oncol; 2020 Jun; 15(6):e87-e88. PubMed ID: 32471566
[No Abstract] [Full Text] [Related]
34. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
[TBL] [Abstract][Full Text] [Related]
35. KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis.
Zhang C; Zhang C; Li J; Wang H
J Thorac Oncol; 2020 Jun; 15(6):e85-e86. PubMed ID: 32471565
[No Abstract] [Full Text] [Related]
36. KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials.
Zhu H; Xie D; Yu Y; Yao L; Xu B; Huang L; Wu S; Li F; Zheng Y; Liu X; Xie W; Huang M; Li H; Zheng S; Zhang D; Qiao G; Chan LWC; Zhou H
Front Oncol; 2021; 11():659200. PubMed ID: 34381706
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC.
Saleh MM; Scheffler M; Merkelbach-Bruse S; Scheel AH; Ulmer B; Wolf J; Buettner R
J Thorac Oncol; 2022 Jan; 17(1):76-88. PubMed ID: 34601169
[TBL] [Abstract][Full Text] [Related]
38. KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?
Dempke WCM; Reck M
Lung Cancer; 2021 Sep; 159():10-17. PubMed ID: 34303275
[TBL] [Abstract][Full Text] [Related]
39. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.
Sun L; Handorf EA; Zhou Y; Borghaei H; Aggarwal C; Bauman J
Lung Cancer; 2024 Apr; 190():107510. PubMed ID: 38432028
[TBL] [Abstract][Full Text] [Related]
40. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
Zhang B; Ma Z; Tan B; Lin N
Expert Opin Ther Targets; 2019 Mar; 23(3):241-250. PubMed ID: 30556750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
